Anadys Pharmaceuticals, Inc. (ANDS) Reports Third Quarter 2007 Financial Results and Operational Highlights
During the third quarter, Anadys recognized $21.0 million of previously deferred revenue, representing the remaining unrecognized portion of the $20 million payment. The Company also reported revenues of $21.5 million for the third quarter of 2007, a significant increase from the $1.1 million revenue reported during the third quarter of 2006. Research and development expenses were $7.6 million for the third quarter of 2007 compared to $5.5 million for the third quarter of 2006. This $2.1 million increase can be attributed to an increase of preclinical trials and the effect of a one-time reimbursement of $1.1 million received during the…